RET-mutated non-small cell lung cancer treated with pralsetinib: a case series

Background: Targeted therapies significantly changed the treatment scenario of non-small cell lung cancer (NSCLC) and improved prognosis of patients harbouring oncogenic drivers. Among these, REarranged during Transfection (RET) fusions are rare, occurring in 1% to 2% of NSCLC. Recent trials revealed the efficacy of novel inhibitors such as pralsetinib and selpercatinib. Due to rarity of RET fusion and novelty of these target therapies, observational and “real world” evidence are missing. The purpose of this series is to point out the impact of treatment with pralsetinib in the clinical setting.